Ozempic users may be making a major weight-loss mistake, new study suggests
GLP-1 receptor agonists like Ozempic and Wegovy are widely used for weight loss and diabetes management. Recent data suggests users may experience decreased activity levels and muscle loss. Many patients face significant weight regain after stopping treatment.
What changed
New reports highlight high rates of weight regain and the risks of incorrect dosing for seniors.
Live updates
-
GLP-1 Weight Loss Users Face Muscle Loss and Weight Regain Risks
confidence 90%GLP-1 receptor agonists like Ozempic and Wegovy are widely used for weight loss and diabetes management. Recent data suggests users may experience decreased activity levels and muscle loss. Many patients face significant weight regain after stopping treatment.
What's confirmed:
- Ozempic and Wegovy belong to a class of drugs called GLP-1 receptor agonists.
- GLP-1 medications were originally developed for the management of type 2 diabetes.
- These drugs work by mimicking the glucagon-like peptide 1 hormone to increase insulin production and slow digestion.
- Some users lose over 20% of their body weight using Ozempic.
Still unconfirmed:
- Between 50% and 80% of GLP-1 users regain weight after stopping the medication.
- Roughly 12% of adults in the U.S. use injectable GLP-1 drugs.
- Most GLP-1 users with type 2 diabetes who stop treatment eventually restart due to weight regain.
- Patients aged 70 and older are often prescribed weight loss medications using dosages intended for 35-year-olds.
-
GLP-1 Users Showing Decline in Physical Activity
confidence 90%Research presented at ENDO 2026 indicates that people using GLP-1 weight loss medications are moving less. Analysis of Fitbit data shows drops in exercise levels and daily step counts despite successful weight loss. Experts warn this trend threatens muscle mass and long-term health.
What's confirmed:
- People taking GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound may experience a decrease in physical activity.
- Fitbit data shows daily step counts and exercise levels dropped after users started these medications.
- GLP-1 medications can reduce muscle mass in addition to fat.
- Research presented at ENDO 2026 shows adults using GLP-1 medications for weight loss significantly reduce their physical activity.
Still unconfirmed:
- Many people taking GLP-1 medications for weight loss are not taking them correctly.
- A gelatin drink marketed as natural Ozempic may aid in portion control.
-
Ozempic users may lose muscle due to decreased activity
confidence 80%Research from ENDO 2026 indicates adults on GLP-1 medications for weight loss are less physically active. This drop in movement can cause muscle loss and harm long-term health. Exercise is recommended to improve outcomes.
What's confirmed:
- Adults using GLP-1 medications for weight loss significantly reduce their physical activity.
- Adding exercise to GLP-1 therapy improves long-term benefits.
Still unconfirmed:
- Social media users have reported a complication known as Ozempic Face.
-
Study Finds GLP-1 Weight Loss Drug Users Are Exercising Less
confidence 100%New research presented at ENDO 2026 shows that adults using GLP-1 medications for weight loss significantly reduce their physical activity. Experts warn that this decline in movement may lead to muscle loss and impact long-term health. Adding exercise to this therapy is said to improve long-term benefits.
What's confirmed:
- Adults using GLP-1 drugs for weight loss such as Ozempic and Wegovy significantly reduced their physical activity.
- A study of 753 GLP-1 users found that daily steps dropped by 560 and exercise decreased by 6 minutes per day after starting treatment.
- GLP-1 medications like semaglutide and tirzepatide reduce both fat and lean muscle mass.
- Adding exercise to GLP-1 therapy improves long-term benefits.
- Researchers expected weight loss from Ozempic to increase exercise, but it did not.